Navigation Links
Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System

ROCHESTER, Minn., Feb. 6 /PRNewswire-USNewswire/ -- Liver transplant is a life saving treatment option for people with end-stage liver disease. Unfortunately, the need for donor livers far exceeds the supply. Each year only about one-third of people who need a donor liver will receive one, and some patients die while waiting. In the February issue of Mayo Clinic Proceedings, physicians explore how the current system for allocating donor organs in the United States affects outcomes for patients with end-stage liver disease.

In the United States, the United Network for Organ Sharing (UNOS) oversees the allocation of donor organs. With the goal of giving available donor organs to the most critically-ill transplant candidates, UNOS adopted a scoring system called the Model for End-Stage Liver Disease (MELD) in February 2002. Unlike past evaluation systems, the MELD score de-emphasizes the length of time a patient has been waiting for a donor organ.

A patient's MELD score is calculated from the results of three laboratory tests. Scores range between 6 and 40, with higher numbers reflecting a more urgent need for transplantation. Research has shown that although the donor liver shortage persists, implementing this allocation system has decreased the number of patients who die while waiting for donor organs.

"Early referral to a liver transplant center no longer provides an advantage for organ allocation. However, it is unclear whether it offers other advantages, or if alternative strategies should be developed regarding timing of referral for liver transplant," writes Jaime Aranda-Michel, M.D., a member of the Mayo Clinic Jacksonville liver transplant team and lead researcher for a Mayo study on this topic.

The Mayo study examined the evaluation practices and denial and acceptance criteria for liver transplant used by the Mayo Clinic Jacksonville Transplant Center after the MELD system was implemented.

"Obtaining a clearer understanding of these issues could result in changes in the approach to referrals for liver transplant," writes Dr. Aranda-Michel.

Mayo researchers examined medical records from 555 patients referred for liver transplant at Mayo Clinic Jacksonville Transplant Center from Jan. 1 through Dec. 31, 2005. A transplant selection committee typically determines patient eligibility for liver transplant using a variety of criteria, including a patient's MELD score. From these 555 patients, 260 were accepted for liver transplant at their first review, and 295 (53 percent) were denied. Among those denied for transplant, 150 (51 percent) were considered too early for liver transplant while the rest were excluded due to other medical conditions and psychosocial issues that affected their eligibility. Patients seeking referral for liver transplant often undergo repeated assessments by selection committees, as their eligibility can change over time or following treatment and/or changes in conditions that led to their initial exclusion.

Significance of the findings

According to Dr. Aranda-Michel, the data from the Mayo study suggest that even though the current donor organ allocation system favors the most critically-ill patients, a broad range of patients could benefit from early referral for liver transplant evaluation.

"Our study suggests that early referral for liver transplant evaluation offers other advantages unrelated to the time patients spend on the liver transplant waiting list. If patients too early for liver transplant were evaluated but not listed, a liver transplant center could initiate management of end-stage liver disease and address psychosocial issues in a subgroup of patients who could also ultimately benefit from liver transplant. Early referral could also lead to the earlier detection and treatment of liver cancer tumors called hepatocellular carcinomas that accompany some forms of chronic liver disease. If these tumors become too large, they can make a patient ineligible for transplant," says Dr. Aranda-Michel.

In an editorial that follows, author Gennaro Selvaggi, M.D., from Miami Transplant Institute at the University of Miami, agrees that while the MELD system has proven to be valuable, those who are responsible for placing patients on transplant lists face many challenges.

"One could argue that keeping a long list of active patients with low MELD scores could burden the system. However, many patients can experience a sudden decompensation of their liver disease, which would rapidly increase their MELD score," writes Dr. Selvaggi.

"In the end, the most important concept advanced by Aranda-Michel is that patients should be referred early and followed up by a team of liver transplant specialists," writes Dr. Selvaggi.

A peer-review journal, Mayo Clinic Proceedings publishes original articles, reviews and editorials dealing with clinical and laboratory medicine, clinical research, basic science research and clinical epidemiology. Mayo Clinic Proceedings is published monthly by Mayo Foundation for Medical Education and Research as part of its commitment to the medical education of physicians. The journal has been published for more than 80 years and has a circulation of 130,000 nationally and internationally. Articles are available online at

To obtain the latest news releases from Mayo Clinic, go to ( is available as a resource for your health stories.

SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):